Peanut Allergy – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Peanut Allergy – Pipeline Review, H2 2017’, provides an overview of the Peanut Allergy pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Peanut Allergy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Peanut Allergy and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Peanut Allergy

The report reviews pipeline therapeutics for Peanut Allergy by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Peanut Allergy therapeutics and enlists all their major and minor projects

The report assesses Peanut Allergy therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Peanut Allergy

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Peanut Allergy

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Peanut Allergy pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Adverum Biotechnologies Inc

Aimmune Therapeutics Inc

Alfacyte Ltd

Allergy Therapeutics Plc

AnaptysBio Inc

ASIT Biotech SA

Astellas Pharma Inc

BioLingus AG

DBV Technologies SA

HAL Allergy BV

Intrommune Therapeutics

Sanofi

Selecta Biosciences Inc

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Peanut Allergy - Overview 6

Peanut Allergy - Therapeutics Development 7

Pipeline Overview 7

Pipeline by Companies 8

Pipeline by Universities/Institutes 10

Products under Development by Companies 11

Products under Development by Universities/Institutes 12

Peanut Allergy - Therapeutics Assessment 13

Assessment by Target 13

Assessment by Mechanism of Action 15

Assessment by Route of Administration 17

Assessment by Molecule Type 19

Peanut Allergy - Companies Involved in Therapeutics Development 21

Adverum Biotechnologies Inc 21

Aimmune Therapeutics Inc 21

Alfacyte Ltd 22

Allergy Therapeutics Plc 22

AnaptysBio Inc 22

ASIT Biotech SA 23

Astellas Pharma Inc 23

BioLingus AG 24

DBV Technologies SA 24

HAL Allergy BV 25

Intrommune Therapeutics 25

Sanofi 25

Selecta Biosciences Inc 26

Peanut Allergy - Drug Profiles 27

aldesleukin - Drug Profile 27

Allergen for Peanut Allergy - Drug Profile 28

Allergen for Peanut Allergy - Drug Profile 29

Allergen for Peanut Allergy - Drug Profile 30

Allergen for Peanut Allergy - Drug Profile 31

ANB-020 - Drug Profile 32

ANN-004 - Drug Profile 35

AR-101 - Drug Profile 36

ASP-0892 - Drug Profile 42

DBV-712 - Drug Profile 44

Drugs to Inhibit CYP11A1 for Peanut Allergy and Asthma - Drug Profile 53

HALMPE-1 - Drug Profile 54

INT-301 - Drug Profile 55

PER-1080 - Drug Profile 56

pnut-ASIT - Drug Profile 57

Polyvac Peanut - Drug Profile 58

PVX-108 - Drug Profile 59

SAR-439794 - Drug Profile 60

SCV-204 - Drug Profile 61

Vaccine 2 for Peanut Allergy - Drug Profile 62

Vaccine for Peanut Allergy - Drug Profile 63

Vaccine for Peanut Allergy - Drug Profile 65

VTC-064 - Drug Profile 66

Peanut Allergy - Dormant Projects 67

Peanut Allergy - Discontinued Products 68

Peanut Allergy - Product Development Milestones 69

Featured News & Press Releases 69

Appendix 83

Methodology 83

Coverage 83

Secondary Research 83

Primary Research 83

Expert Panel Validation 83

Contact Us 83

Disclaimer 84

List of Tables

List of Tables

Number of Products under Development for Peanut Allergy, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Products under Development by Companies, H2 2017

Products under Development by Universities/Institutes, H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Peanut Allergy – Pipeline by Adverum Biotechnologies Inc, H2 2017

Peanut Allergy – Pipeline by Aimmune Therapeutics Inc, H2 2017

Peanut Allergy – Pipeline by Alfacyte Ltd, H2 2017

Peanut Allergy – Pipeline by Allergy Therapeutics Plc, H2 2017

Peanut Allergy – Pipeline by AnaptysBio Inc, H2 2017

Peanut Allergy – Pipeline by ASIT Biotech SA, H2 2017

Peanut Allergy – Pipeline by Astellas Pharma Inc, H2 2017

Peanut Allergy – Pipeline by BioLingus AG, H2 2017

Peanut Allergy – Pipeline by DBV Technologies SA, H2 2017

Peanut Allergy – Pipeline by HAL Allergy BV, H2 2017

Peanut Allergy – Pipeline by Intrommune Therapeutics, H2 2017

Peanut Allergy – Pipeline by Sanofi, H2 2017

Peanut Allergy – Pipeline by Selecta Biosciences Inc, H2 2017

Peanut Allergy – Dormant Projects, H2 2017

Peanut Allergy – Discontinued Products, H2 2017

List of Figures

List of Figures

Number of Products under Development for Peanut Allergy, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Number of Products by Targets, H2 2017

Number of Products by Stage and Targets, H2 2017

Number of Products by Mechanism of Actions, H2 2017

Number of Products by Stage and Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Molecule Types, H2 2017

Number of Products by Stage and Molecule Types, H2 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports